AI Image
UniQure's gene therapy slows Huntington's progression after 4 years
STAT • • business
Key Points:
- UniQure's experimental gene therapy AMT-130 for Huntington’s disease showed a 44% slowing in disease progression four years after brain implantation, according to the company’s latest report.
- The treatment's benefit has decreased compared to data from one year ago, raising concerns about the long-term durability of the therapy.
- The observed difference in disease progression was not statistically significant in the recent analysis.
- This update comes as the FDA begins reviewing UniQure’s marketing application for AMT-130.
